A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Summary

A Phase 2, multi center, open label, dual cohort study to evaluate the efficacy and safety of lorlatinib (PF 06463922) monotherapy in ALK inhibitor treated locally advanced or metastatic ALK positive non small cell lung cancer patients in China

Timeline

Start

2019-04-28

Primary completion

2020-08-10

Completion

2024-10-21

Publications

• Lu S, Zhou Q, Liu X, Du Y, Fan Y, Cheng Y, He S, Zhao H, Li H, Wu YL. Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK-Positive Non-small Cell Lung Cancer. Clin Lung Cancer. 2024 Nov;25(7):e295-e303.e4. doi: 10.1016/j.cllc.2024.04.017. Epub 2024 Apr 30.
• Niu R, Zhang Y, Pang J, Zhou Q, Lei Y, Du Y. Effective treatment of advanced lung adenocarcinoma with paraneoplastic leukemoid reaction with Lorlatinib: a case report. Front Oncol. 2024 Jan 26;14:1341233. doi: 10.3389/fonc.2024.1341233. eCollection 2024.

Drugs

Indications